Treatment of Benign Prostatic Hyperplasia in Patients with Cardiovascular Disease

  title={Treatment of Benign Prostatic Hyperplasia in Patients with Cardiovascular Disease},
  author={Vincent M. Santillo and Franklin C. Lowe},
  journal={Drugs \& Aging},
Pharmacological management is the most common therapeutic approach for patients with benign prostatic hyperplasia and α-adrenoceptor antagonists are the most commonly prescribed initial treatment. Although all of the α-adrenoceptor antagonists produce similar improvements in symptom scores and urinary flow rates, they have different adverse effect profiles, especially with respect to the cardiovascular system. The older α-adrenoceptor antagonists, terazosin and doxazosin, were initially… 
Cardiovascular Effects of Noncardiovascular Drugs
This review discusses some cardiovascular manifestations of drugs used for noncardiovascular indications that arise indirectly from drug interactions that cause an increase or decrease in the concentration of a cardiovascular drug.
Supplemental Studies for Cardiovascular Risk Assessment in Safety Pharmacology: A Critical Overview
This critical review aims at discussing the usefulness, relevance, advantages, and limitations of some preclinical in vivo, in vitro, and in silico models, with high predictive values and currently used in supplemental safety studies.
Reversible visual loss caused by combination therapy of alfuzosin and finasteride in a patient with uveitic glaucoma
Optic nerves affected by glaucoma may be more vulnerable to systemic hypotension, resulting in an increased risk of further ischemic injury.
Atorvastatin attenuates testosterone‐induced benign prostatic hyperplasia in rats: role of peroxisome proliferator‐activated receptor‐γ and cyclo‐oxygenase‐2
Investigation of the protective effect of atorvastatin in combination with celecoxib (CEL) or pioglitazone (PIO) on testosterone‐induced BPH in rats showed that ator Vastatin attenuated testosterone‐ induced BPH, and synergistic effect was observed when atorVastatin was combined with Celecoxib.
Contemporary Reviews in Cardiovascular Medicine
Summary Titin is responsible for the passive and restoring force of thecardiac sarcomere and makes a major contribution to thediastolicwallstressoftheLV,thelevelofwhichcanbetunedthrough differential
A validated potentiometric method for determination of alfuzosin hydrochloride in pharmaceutical and biological fluid samples
Recently, graphene nanosheet has attracted the most attention for the potential applications in various electrochemical sensing fields to biomedical diagnosis and therapy due to its large theoretical


Analysis of the functional role of ADAMTS enzymes in prostate cancer
It can be concluded that an alpha1-AR antagonist with a low potential to interfere with blood pressure regulation and to induce cardiovascular AEs, also in patients with cardiovascular comorbidity and/or comedication, can be considered a first-choice treatment option in LUTS/BPH.
The clinical efficacy and tolerability of doxazosin standard and gastrointestinal therapeutic system for benign prostatic hyperplasia
Both doxazosin standard and GITS are well‐tolerated, long‐term therapies that are equally effective in younger and older men, and not associated with causing sexual dysfunction.
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
Long-term combination therapy with doxazosin and finasteride was safe and reduced the risk of overall clinical progression of benign prostatic hyperplasia significantly more than did treatment with either drug alone.
α1-Adrenergic Receptors and Their Inhibitors in Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia
A comprehensive overview of the role of α1-adrenergic receptors (α1ARs) as critical mediators of lower urinary tract symptoms (LUTS) and pathophysiology in benign prostatic hyperplasia (BPH) is provided, and the pharmacological antagonists of α 1ARs are reviewed.
Side Effects of Terazosin in the Treatment of Symptomatic Benign Prostatic Hyperplasia
  • F. Lowe
  • Medicine
    Southern medical journal
  • 1997
It is confirmed that terazosin can be administered safely to a population of men with symptomatic benign prostatic hyperplasia with minimal clinically significant side effects.
The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
In men with benign prostatic hyperplasia, terazosin was effective therapy, whereas finasteride was not, and the combination of terazOSin and finasterside was no more effective than terazoshin alone.